Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-4A06
- Development stage
- Preclinical
- Lead developer
- University of California, San Francisco
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-4A06 is a CDCP1-targeted radiopharmaceutical consisting of the monoclonal antibody 4A06 labeled with the beta-emitting radioisotope Lutetium-177. It is designed to treat cancers that overexpress CUB domain-containing protein 1 (CDCP1), such as the basal/squamous subtype of bladder cancer. The 4A06 antibody binds to the extracellular domain of CDCP1, allowing for the targeted delivery of ionizing radiation to tumor cells, which results in DNA damage and subsequent cell death. Preclinical studies have shown that 177Lu-4A06 effectively inhibits tumor growth in bladder cancer xenograft models, including those that do not express other common targets like TROP2 or NECTIN4.
- Other names
- Lutetium-177 4A06Lutetium177 4A06Lutetium 177 4A06[177Lu]Lu-4A06
02
Targets
CDCP1 (CUB domain-containing protein 1)
Beyond the preview
Go deeper on 177Lu-4A06.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-4A06.